Open Access<p>Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report</p>
Author(s) -
Lina He,
Fengchun Zhang,
Yue Ma,
Li Zuo,
Yingchun Xu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s252117
Subject(s) - medicine , trastuzumab , oncology , breast cancer , regimen , pertuzumab , taxane , chemotherapy , paclitaxel , vinorelbine , cancer , cisplatin
Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotinib is a newly irreversible tyrosine kinase inhibitor (TKI) that is well developed for the treatment of HER2-positive advanced breast tumors.